Skip to main content

Table 4 Clinical data of included studies for the efficacy of antiviral treatment on all-cause and liver-specific mortality in patients with CHC

From: Impact of antiviral therapy on hepatocellular carcinoma and mortality in patients with chronic hepatitis C: systematic review and meta-analysis

Study Nationality Age Duration of follow up Study format Genotype NOS Treatment Death/Total treatment Death/Control Histology
Benvegnù L et al. (1998) [27] Italy Tx: 56.7, control: 59.5 (mean) mean 71.5 months P unknown 8 IFN a3/75 a15/77 Child A LC
Ikeda K et al. (2001) [33] Japan 57 (median) median 7.6 years R unknown 7 IFN-α or IFN-β 20/113 a12/113 266/581 a124/581 LC
Gramenzi A et al. (2001) [34] Italy Tx: 57.9, control: 58.1 (mean) median 55–58 months P unknown 7 IFN-α a7/72 9/72 a8/72 LC (mainly Child A)
Nishiguchi S et al. (2001) [35] Japan Tx: 54.7, control: 57.3 (mean) mean 8.2 years RCT 75.6% type 2   IFN-α 5/45 26/45 unknown
Testino G et al. (2002) [16] Italy Tx: 55.3, control: 56.8 (mean) mean 95.4 months R 55% type 1b, 45% type 2 8 IFN-α 1/51 9/71 Child A LC
Yosida H et al. (2002) [47] Japan Tx: 49.5, control: 54.6 (mean) mean 5.4 years R unknown 8 IFN-α or IFN-β 56/2430 a35/2430 30/459 a23/459 F3,4: 32.2% in Tx, 31.6% in control, 26.3% in SVR, 35.2% in no SVR
Imazeki F et al. (2003) [48] Japan Tx: 49.2, control: 53.1 (mean) mean 8.2 years R 73.9% type 1 8 IFN-α or IFN-β 33/355 a19/355 15/104 a12/104 F3,4: 26.7% in Tx, 29.8% in control,
Coverdale SA et al. (2004) [36] Australia Tx: 37, control: 38 (median) median 9 years P 39.6% type 1 7 IFN-α a36/384 a12/71 Scheuer fibrosis score 2
Kasahara A et al. (2004) [17] Japan Tx: 53, control: 54 (median) mean 6 years R unknown 8 IFN 101/2698 a69/2698 52/256 a42/256 F3,4: 38.7% in Tx, 48% in control, 28.6% in SVR, 43% in no SVR
Shiratori Y et al. (2005) [38] Japan Tx: 57, control: 61 (median) median 6.8 years P 71.9% type 1b 8 IFN-α or lymphoblastoid 45/271 a32/271 24/74 a19/74 unknown
Yu ML et al. (2006) [39] Taiwan Tx: 46.9, control: 43.6 (mean) mean 5.18–5.15 years R 46.2% type 1 8 IFN-α with or without RBV 16/1057 a14/1057 12/562 a10/562 LC 15.6% in Tx, 12.1% in control
Di Martino V et al. (2011) [41] France unknown median 59 months R 57.9% type 1 7 IFN with or without RBV, or PegIFN with RBV 9/184 a5/184 20/194 a4/184 55.5% F2 or greater
Yamasaki K et al. (2012) [49] Japan 60.9 (mean) median 11.5 years P 59.9% type 1b 7 IFN-α or β or lymphoblastoid with or without RBV 25/152 a6/152 90/199 a32/199 unknown
Maruoka D et al. (2012) [43] Japan 50.4–54 (mean) mean 9.9 years R 73.6% type 1 8 IFN-α/IFN-β with or without RBV 84/577 a52/577 37/144 a30/144 F3,4: 24.3% in Tx, F4: 43.1% in control
Cozen ML et al. (2013) [44] US 50.98 (mean) mean 10 years R 68.7% type 1 8 IFN-α with or without RBV 31/159 47/199 F3,4: 19% (30.2% in Tx, 10.1% in control)
Aleman S et al. (2013) [45] Sweden 51 (mean) mean 5.3 years R 50% type 1 8 PegIFN with RBV 59/303 a39/303 18/48 a16/48 LC
Kutala BK et al. (2015) [50] France 50 (median) median 5.5 years R 55.7% type 1 8 IFN/PegIFN with or without RBV 30/325 19/102 F3,4: 100%
Cozen ML et al. (2016) [46] US 51.4 (mean) mean 8.5 years P 71.6% type 1 or 4 8 IFN-α with RBV 112/692 488/1519 LC 15.8% in Tx, 5.3% in control
  1. a: Liver-specific death, CHC chronic hepatitis C, NOS Newcastle-Ottawa scale, Tx treatment group, R retrospective cohort study, P prospective cohort study, RCT randomized controlled study, IFN interferon, PegIFN pegylated interferon, RBV ribavirin, LC liver cirrhosis, SVR sustained virologic response